Anti-mycobacterial drugs
AssigneeThe Florida International University Board of Trustees
InventorsJOONG HO MOON, MICHELLE MIRANDA
Life of this patent
Estimating the term…
Abstract
The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.
Claims22
1-2. (canceled)
An oligo(carbamoylated guanidine) (OCG) comprising a structure of
- wherein 3≤n≤50;
- X is alkylene, heteroatom interrupted alkylene, arylene or a combination thereof;
- each Y is linear or cyclic alkylene, one or more heteroatom interrupted alkylene, cycloalkylene, arylene, heteroarylene, or a combination thereof, wherein the heteroatom is O, S, NH, or a combination thereof;
- and R1 and R2 are each independently H;
- substituted or unsubstituted linear, branched, or cyclic alkyl;
- one or more heteroatom interrupted substituted or unsubstituted linear branched or cyclic alkyl;
- unsubstituted or substituted aryl;
- unsubstituted or substituted heteroarylene;
- or a combination thereof;
- or a salt thereof.
A pharmaceutical composition comprising the OCG or a salt thereof according to claim 1.
A method of treating tuberculosis in a subject, the method comprising administering an effective amount of the pharmaceutical composition comprising the OCG according to claim 1 and an anti-tuberculosis drug selected from CIP, CLZ, BDQ, VER, RIF, CIP, linezolid, INH, PZA, RPT, fluoroquinolones and ethambutol.
(canceled)
Dependencies are inferred from the claim text.